A Study of Dideoxycytidine Plus Zidovudine in the Treatment of AIDS or Advanced AIDS Related Complex (ARC)

This study has been completed.
Sponsor:
Collaborator:
Hoffmann-La Roche
Information provided by:
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00000978
First received: November 2, 1999
Last updated: August 6, 2008
Last verified: August 1992
  Purpose

To determine the safety, tolerability, and activity of zidovudine (AZT) and zalcitabine (dideoxycytidine; ddC) and the bloodstream levels of these drugs in patients with AIDS or advanced AIDS-related complex (ARC).

Treatments using AZT alternating with ddC are being evaluated in ongoing trials with a goal of reducing the toxicity of each while maintaining antiviral effects. In addition, AZT and ddC may work together in a way that both drugs can be taken at lower doses or less frequent intervals when given together. If the doses can be reduced, then toxicity associated with long-term use of one drug may be reduced. Combination of AZT and ddC might reduce the likelihood of the emergence of resistant mutants. Recent studies indicate a reduced sensitivity of HIV isolated from patients after prolonged AZT therapy. Although the clinical significance of this finding is not clear, it would indicate that these combination studies are all the more important. HIV strains with decreased sensitivity to AZT are still sensitive to ddC.


Condition Intervention Phase
HIV Infections
Drug: Zidovudine
Drug: Zalcitabine
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: An Open-Label, Randomized, Dose-Finding, Multicenter Trial of Dideoxycytidine (ddC) Administered Concurrently With Zidovudine (AZT) in the Treatment of AIDS or Advanced ARC

Resource links provided by NLM:


Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Estimated Enrollment: 68
Detailed Description:

Treatments using AZT alternating with ddC are being evaluated in ongoing trials with a goal of reducing the toxicity of each while maintaining antiviral effects. In addition, AZT and ddC may work together in a way that both drugs can be taken at lower doses or less frequent intervals when given together. If the doses can be reduced, then toxicity associated with long-term use of one drug may be reduced. Combination of AZT and ddC might reduce the likelihood of the emergence of resistant mutants. Recent studies indicate a reduced sensitivity of HIV isolated from patients after prolonged AZT therapy. Although the clinical significance of this finding is not clear, it would indicate that these combination studies are all the more important. HIV strains with decreased sensitivity to AZT are still sensitive to ddC.

Patients are randomly assigned to one of six treatment groups of various dose combinations of AZT and ddC. Patients are evaluated every week for the first 10 weeks and biweekly thereafter.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

Concurrent Medication:

Allowed:

  • Aerosolized pentamidine 300 mg per 4 weeks.
  • Drugs unlikely to cause increased toxicity with either study drug and unlikely to cause peripheral neuropathy.
  • Drugs with little nephrotoxicity, hepatotoxicity, or cytotoxicity, that patient has been taking and tolerating well for ongoing condition.
  • Acyclovir (= or < 600 mg/day, orally).
  • Ketoconazole (= or < 400 mg/day).
  • Nystatin (occasional).
  • Acetaminophen or nonsteroidal antiinflammatory agents (low dose).
  • Drugs that could possibly cause serious additive toxicity when coadministered with either study drug, but unlikely to cause peripheral are allowed only if their use is anticipated for treatment of acute intercurrent illness or opportunistic infections.
  • Allowed only with a study drug interruption of up to 21 days per episode, for a total of 42 days for the study:
  • Acyclovir (> 600 mg/day).
  • Experimental drugs including ganciclovir.
  • Fluconazole.
  • Systemic pentamidine.
  • Pyrimethamine.
  • Triple sulfa.
  • Ansamycin.
  • Prolonged continuous use of high-dose nonsteroidal antiinflammatory agents.
  • Acetaminophen.
  • Amphotericin.
  • Foscarnet.

Concurrent Treatment:

Allowed:

  • Radiation therapy if unlikely to cause peripheral neuropathy if their use is anticipated for treatment of acute intercurrent illness or opportunistic infection.
  • Transfusion for anemia.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Active opportunistic infections requiring treatment with unallowed drugs.
  • Symptomatic visceral Kaposi's sarcoma (KS), progression of KS within month prior to study entry, or with concurrent neoplasms other than KS, basal cell carcinoma of the skin, or in situ carcinoma of the cervix.
  • History of peripheral neuropathy or any significant signs or symptoms of neurological disease, or abnormality indicative of peripheral neuropathy.
  • Significant cardiac disease defined as history of ventricular arrhythmias requiring medication, prior myocardial infarction, or history of angina or ischemic changes on electrocardiogram.
  • Significant liver disease as defined by transaminase levels or by history of cirrhosis or ascites.
  • Significant renal disease defined by serum creatinine.

Concurrent Medication:

Excluded:

  • Experimental drugs including fluconazole, and foscarnet.
  • Immunomodulators including interferon, interleukins, or systemic corticosteroids.
  • Ganciclovir.
  • Neurotoxic drugs.
  • Drugs that could potentially cause peripheral neuropathy, including chloramphenicol, cisplatin, iodoquinol, dapsone, phenytoin, disulfiram, ethionamide, glutethimide, gold, hydralazine, isoniazid, metronidazole, vincristine, and nitrofurantoin.
  • Excluded within 4 weeks of study entry:
  • Drugs that have caused significant nephrotoxicity or significant hepatotoxicity (as defined by transaminases).

Concurrent Treatment:

Excluded:

  • Transfusion dependent.

Patients are excluded if unwilling or unable to sign informed consent.

Prior Medication:

Excluded:

  • Zidovudine (AZT).
  • Dideoxycytidine (ddC).
  • Any other nucleoside antiretrovirals.

Positive antibody to HIV using any federally licensed ELISA test kit. Diagnosis of AIDS or AIDS-related complex (ARC).

Active substance or alcohol abuse.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000978

Locations
United States, California
Univ of California / San Diego Treatment Ctr
San Diego, California, United States, 921036325
United States, Florida
Univ of Miami School of Medicine
Miami, Florida, United States, 331361013
Sponsors and Collaborators
Hoffmann-La Roche
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00000978     History of Changes
Other Study ID Numbers: ACTG 106, Protocol N3447
Study First Received: November 2, 1999
Last Updated: August 6, 2008
Health Authority: United States: Federal Government

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):
Zalcitabine
Drug Therapy, Combination
Acquired Immunodeficiency Syndrome
AIDS-Related Complex
Zidovudine

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
AIDS-Related Complex
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Zalcitabine
Zidovudine
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses
Anti-HIV Agents

ClinicalTrials.gov processed this record on April 15, 2014